Christopher Gilfillan

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Stefano Del Prato, Steven E. Kahn, Imre Pávó et al. · The Lancet · 2021 · 642 citations

Medicine, Pharmacology, Pharmacotherapy +16

The high burden of inpatient diabetes mellitus: the Melbourne Public Hospitals Diabetes Inpatient Audit

Leon A. Bach, Elif I. Ekinci, Dennis Engler et al. · The Medical Journal of Australia · 2014 · 89 citations · Full text

Medicine, Internal Medicine, Clinical Medicine +10

Real-world artificial intelligence-based opportunistic screening for diabetic retinopathy in endocrinology and indigenous healthcare settings in Australia

Jane Scheetz, Dilara Koca, Myra B. McGuinness et al. · Scientific Reports · 2021 · 81 citations · Full text

Medicine, Health Informatics, Ophthalmology +17

Fracture prevention strategies in patients presenting to Australian hospitals with minimal‐trauma fractures: a major treatment gap

Helena Teede, I. A. Jayasuriya, Christopher Gilfillan · Internal Medicine Journal · 2007 · 58 citations

Medicine, Emergency Medicine, Orthopaedic Surgery +17

Cetuximab plus radiotherapy for the treatment of locally advanced squamous cell carcinoma of the head and neck

Susan Griffin, Simon Walker, Mark Sculpher et al. · Health Technology Assessment · 2009 · 52 citations · Full text

Medicine, Oncology, Radiation Oncology +15